Canada markets open in 3 hours

BioVaxys Technology Corp. (BVAXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.08000.0000 (0.00%)
At close: 03:34PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • T
    Tal
    VANCOUVER, BC, Sept. 8, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Craig Loverock has joined the Company as Chief Financial Officer. Mr. Loverock is replacing Mr. Lachlan McLeod, who has been the acting CFO following the transition from Lions Bay Mining Inc. to BioVaxys in October 2020. Mr. McLeod will be resuming his full-time duties with Fehr & Associates CPA.

    Mr. Loverock is a licensed CPA, with more than 25 years of accounting and financial management experience in Canada, the United States and the United Kingdom. He currently provides senior financial and advisory services as the Chief Financial Officer to several other Canadian public and private corporations. He also currently serves on the Board and Chair of the Audit Committee for two other Canadian companies, one listed on NASDAQ.

    James Passin, BioVaxys CEO, stated, "With extensive financial reporting and management experience in a number of CSE, TSXV and NASDAQ-listed companies, Craig Loverock is an excellent addition to our leadership team as BioVaxys prepares for a wave of potential growth and development. I want to thank outgoing CFO Lachlan McCleod for his invaluable contributions to BioVaxys since the company's initial public listing and wish him the best of luck in the future.
  • T
    Tal
    hey management - what r u doing with our money. do you work every day
  • T
    Tal
    0.0925+0.0165 (+21.71%)
    As of 03:11PM EDT. Market open.
  • T
    Tal
    why don't you tell your investor what the hec you are doing. you are not saying anything. What are you doing. Why do get people's investment. someone will notice. report , do something.
  • T
    TheyStillCallMeBruce
    Not sure what happened there, but sold some at .12 and bought back even more at .90, .95 and .10

    GLTA
  • K
    Kelvin
    This stock seems playing dead everyday. No news, no progress, no nothing except debt, more dilution.
    Bought in 23,000 shares at $0.23 and look like dead in the water for years to come, to revover. No covid vaccine, no vaginal treatment, no noise, dead silent
  • T
    TheyStillCallMeBruce
    .50 warrants extended until Jan 2023, curious…Expecting some trial data in Jan maybe?
  • A
    AK
    It is the right time to buy this share now before it gets late. It has small market cap now. It has planned for production for the cancer vaccine. The Covid vaccine is on the process. After this success this Biovax will be one of the leading company in Biotech Industry in Canada. I think it is a perfect buy.
  • r
    ryan
    gotta love it. fda approval incoming
  • S
    Stefan
    🚀 headed to the moon!
  • L
    Lee
    Look at the volume on the up days (high) and the volume on the down days (low). It's all bullish right now. Those with patience will be rewarded! I'm talking at least 2 yrs here.
  • D
    Dub
    Y’all are sleeping on this one...
  • r
    ryan
    HALTED
  • r
    ryan
    in before the pump
  • J
    Jack
    Someone continues to drive significant accumulation volume. Big announcement and sp jump to $$ looming?
  • C
    Cameron
    FDA approval next week load up
  • J
    Jack
    Excellent interview with Dr. David Berd, inventor of the Biovaxys technology ........ https://soundcloud.com/rxradiofm/episode-118-inventing-a-vaccine-a-conversation-with-the-chief-medical-officer-of-biovaxys
  • J
    Jack
    BIOV needs to step on the accelerator and advance beyond the research study and speech mode.